Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice
- 1 December 2008
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 6 (12), 2048-2054
- https://doi.org/10.1111/j.1538-7836.2008.03187.x
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort studyBlood, 2007
- Polymorphisms in the CTLA‐4 gene and inhibitor development in patients with severe hemophilia AJournal of Thrombosis and Haemostasis, 2007
- Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia ABlood, 2006
- Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitorsHaemophilia, 2006
- Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophiliaHaemophilia, 2006
- Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia ABlood, 2006
- Translating Clinical Research into Clinical Practice: Impact of Using Prediction Rules To Make DecisionsAnnals of Internal Medicine, 2006
- Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia ABlood, 2006
- The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor developmentHaemophilia, 2001
- Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentratesHaemophilia, 1999